Why some people are more sensitive to DNA‑damaging chemicals

Modeling the Responsiveness of Sensitive Populations to Genotoxic Agents Using DNA Repair Inhibitors

['FUNDING_SBIR_2'] · LITRON LABORATORIES, LTD. · NIH-11253560

This project tests whether blocking different DNA repair pathways in human cells can mimic people who are unusually sensitive to chemicals that damage DNA.

Quick facts

Phase['FUNDING_SBIR_2']
Study typeNih_funding
SexAll
SponsorLITRON LABORATORIES, LTD. (nih funded)
Locations1 site (ROCHESTER, UNITED STATES)
Trial IDNIH-11253560 on ClinicalTrials.gov

What this research studies

Researchers use a standard human blood cell line with normal p53 and expose those cells to chemicals while adding small‑molecule drugs that block each major DNA repair pathway to model sensitive people. By comparing chemical responses with and without these repair inhibitors, they aim to reveal which repair defects make cells much more vulnerable. The platform is lab‑based and uses a panel of inhibitors chosen to cover base excision repair, nucleotide excision repair, homologous recombination, and other pathways. Results are intended to help predict variable sensitivity across human populations and clarify molecular mechanisms of toxicity.

Who could benefit from this research

Good fit: Although not a clinical trial, the findings will be most relevant to people worried about chemical exposures, especially those with known or suspected DNA repair disorders or unusual sensitivity to environmental toxins.

Not a fit: People seeking immediate medical treatment for a health condition or those with unrelated diseases should not expect direct clinical benefit from this lab-based project.

Why it matters

Potential benefit: If successful, this approach could help identify groups of people at higher risk from environmental or occupational chemical exposures and inform safer exposure limits or protections.

How similar studies have performed: Prior laboratory work shows DNA repair capacity strongly affects sensitivity to genotoxins, but using a single cell line combined with a comprehensive panel of repair inhibitors to model sensitive subpopulations is a relatively new and less-tested strategy.

Where this research is happening

ROCHESTER, UNITED STATES

Researchers

About this research

  1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
  2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
  3. For full project details, budget, and progress reports, visit the official NIH RePORTER page below.

View on NIH RePORTER →

Last reviewed 2026-05-15 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.